StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Reaktion

Quinoline-3-boronic acid → N-(1-methylpiperidin-4-yl)-1-(4-(3-oxo-9-(quinolin-3-yl)-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)piperidine-4-carboxamide

HRID 1944614
Drucken

Reaktionsgleichung

Reaktionsgleichung von HRID 1944614
Br[C:2]1[CH:11]=[CH:10][C:9]2[N:8]=[CH:7][C:6]3[NH:12][C:13](=[O:42])[CH2:14][N:15]([C:16]4[CH:21]=[CH:20][C:19]([N:22]5[CH2:27][CH2:26][CH:25]([C:28]([NH:30][CH:31]6[CH2:36][CH2:35][N:34]([CH3:37])[CH2:33][CH2:32]6)=[O:29])[CH2:24][CH2:23]5)=[C:18]([C:38]([F:41])([F:40])[F:39])[CH:17]=4)[C:5]=3[C:4]=2[CH:3]=1.[N:43]1[C:52]2[C:47](=[CH:48][CH:49]=[CH:50][CH:51]=2)[CH:46]=[C:45](B(O)O)[CH:44]=1.CC(C1C=C(C(C)C)C(C2C(P(C(C)(C)C)C(C)(C)C)=CC=CC=2)=C(C(C)C)C=1)C>O1CCOCC1.C(=O)([O-])[O-].[Na+].[Na+]>[CH3:37][N:34]1[CH2:33][CH2:32][CH:31]([NH:30][C:28]([CH:25]2[CH2:24][CH2:23][N:22]([C:19]3[CH:20]=[CH:21][C:16]([N:15]4[C:5]5[C:4]6[CH:3]=[C:2]([C:45]7[CH:44]=[N:43][C:52]8[C:47]([CH:46]=7)=[CH:48][CH:49]=[CH:50][CH:51]=8)[CH:11]=[CH:10][C:9]=6[N:8]=[CH:7][C:6]=5[NH:12][C:13](=[O:42])[CH2:14]4)=[CH:17][C:18]=3[C:38]([F:41])([F:40])[F:39])[CH2:27][CH2:26]2)=[O:29])[CH2:36][CH2:35]1
KomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion

Komponenten

6

Edukt 3

HCID 2734663Quinoline-3-boronic acidHCID 11618717Di-tert-butyl(2',4',6'-tris(propan-2-yl)-(1,1'-biphenyl)-2-yl)phosphaneHCID 585250731-(4-(9-bromo-3-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)-N-(1-methylpiperidin-4-yl)piperidine-4-carboxamide

Produkt 1

HCID 46191629
N-(1-methylpiperidin-4-yl)-1-(4-(3-oxo-9-(quinolin-3-yl)-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)piperidine-4-carboxamide
Ausbeute 3,1 %

Reagenzien, Katalysatoren, Lösungsmittel 2

HCID 10340Sodium CarbonateLösungsmittelHCID 312751,4-DioxaneLösungsmittel

Versuchsvorschrift

To a solution of 8.5 1-(4-(9-bromo-3-oxo-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)-N-(1-methylpiperidin-4-yl)piperidine-4-carboxamide (46 mg, 0.07 mmol, 1 equiv.) in dioxane (2 mL) and 1N sodium carbonate solution (0.6 mL) in a sealed tube at room temperature was added 7 quinolin-3-yl-boronic acid (24 mg, 0.14 mmol, 2 equiv.), t-butyl-Xphos (3 mg, 0.007 mmol, 0.1 equiv.), and PdCl2(Ph3P)2 (4.9 mg, 0.007 mmol, 0.1 equiv.). The resulting mixture was degassed, sealed and heated overnight to 100° C. Upon cooling to room temperature, the reaction mixture was filtered through celite and washed with EtOAc (2 mL). The collected solution was evaporated and the residue was purified via HPLC to afford the desired product 8.6 N-(1-methylpiperidin-4-yl)-1-(4-(3-oxo-9-(quinolin-3-yl)-3,4-dihydropyrazino[2,3-c]quinolin-1(2H)-yl)-2-(trifluoromethyl)phenyl)piperidine-4-carboxamide 1.5 mg. LC-MS: (M+H) 694.40

Aufarbeitung

  1. customThe resulting mixture was degassed
  2. customsealed
  3. temperatureheated overnight to 100° C
  4. filtrationthe reaction mixture was filtered through celite
  5. washwashed with EtOAc (2 mL)
  6. customThe collected solution was evaporated
  7. customthe residue was purified via HPLC

Quellen und Nachweise

ORD-Eintrag
ord-464258777a394fbbaff6db7b7ae7a31b
Quelldatensatz
uspto-grants-2013_03
DOI
10.6084/m9.figshare.5104873.v1
Patentnummer
US08394818B2

Notizen zur Reaktion

Auf dieser SeiteKomponentenVersuchsvorschriftAufarbeitungQuellen und NachweiseNotizen zur Reaktion